BioFactura, Inc. today announced a contract option activation of over $13 million by the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, as part of BioFactura’s prime contract
Civica To Create 186 Jobs With New Virginia Pharmaceutical Facility
Published on :Pharmaceutical manufacturer Civica Inc. will invest $124.5 million to establish its first in-house pharmaceutical manufacturing operation in the City of Petersburg, VA. The project will create 186 new jobs.
5 Questions with Rachel Rath, MBA, MPH, Director, BARDA Alliance for Johnson & Johnson Innovation, JLABS @ Washington, DC
Published on :Rachel is the Director of the BARDA Alliance for Johnson & Johnson Innovation, based at JLABS @ Washington, DC. In this role, she is responsible for managing the BLUE KNIGHT™ collaboration between Johnson & Johnson Innovation – JLABS (JLABS) and the Biomedical Advanced Research and Development Authority (BARDA). BLUE KNIGHT™ focuses on addressing public-health threats and emerging infectious diseases by supporting companies with emerging science and technology solutions that aim to improve health security and responses.
5 Questions with Nick Droste, Supervisor, Emergent BioSolutions Postfill Manufacturing Supervisor
Published on :Nick Droste is part of the postfill manufacturing team at the Emergent BioSolutions Baltimore Camden site, where he leads visual inspection operations for Emergent’s growing Contract Development Manufacturing and Organization (CDMO) efforts and in support of their new partnership with the Biomedical Advanced Research and Development Authority (BARDA) COVID-19 vaccine development operations.